Evidence map›Paper›PMID 37226775›Full record

ArticleStroke2023

Poststroke Lung Infection by Opportunistic Commensal Bacteria Is Not Mediated by Their Expansion in the Gut Microbiota.

Laura Díaz-Marugan, Mattia Gallizioli, Leonardo Márquez-Kisinousky, Silvia Arboleya, Annalaura Mastrangelo, Francisca Ruiz-Jaén, Jordi Pedragosa, Climent Casals, Francisco Javier Morales, Sara Ramos-Romero and 11 more

Open access · hybridAbstract read
In one paragraph

Article in Stroke, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 1 country.

Laura Díaz-MaruganInstituto de Investigaciones Biomédicas de Barcelona (IIBB) (L.D.-M., M. Gallizioli, L.M.-K., F.R.-J., J.P., C.J., A.M.P.), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, Spain.ORCID 0000-0002-7589-2547
Mattia GallizioliInstituto de Investigaciones Biomédicas de Barcelona (IIBB) (L.D.-M., M. Gallizioli, L.M.-K., F.R.-J., J.P., C.J., A.M.P.), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, Spain.ORCID 0000-0001-9245-914X
Leonardo Márquez-KisinouskyInstituto de Investigaciones Biomédicas de Barcelona (IIBB) (L.D.-M., M. Gallizioli, L.M.-K., F.R.-J., J.P., C.J., A.M.P.), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, Spain.
Silvia ArboleyaInstituto de Productos Lácteos de Asturias (IPLA-CSIC), CSIC, Villaviciosa, Spain (S.A., M. Gueimonde, C.G.d.l.R.-G.).
Annalaura MastrangeloCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (A.M., D.S.).
Francisca Ruiz-JaénInstituto de Investigaciones Biomédicas de Barcelona (IIBB) (L.D.-M., M. Gallizioli, L.M.-K., F.R.-J., J.P., C.J., A.M.P.), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, Spain.ORCID 0009-0006-7933-2287
Jordi PedragosaInstituto de Investigaciones Biomédicas de Barcelona (IIBB) (L.D.-M., M. Gallizioli, L.M.-K., F.R.-J., J.P., C.J., A.M.P.), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, Spain.
Climent CasalsInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain (L.D.-M., M. Gallizioli, L.M.-K., F.R.-J., J.P., C.C., C.J., X.U., A.C., F.M.-M., A.M.P.).
Francisco Javier MoralesServei de Microbiología, Hospital Clínic, Barcelona, Spain (C.C., F.J.M.).
Sara Ramos-RomeroInstitut de Química Avançada de Catalunya (IQAC) (S.R.-R., J.L.T.), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, Spain.
Sara TraserraDepartament de Biologia Cel.lular, Fisiologia i Inmunologia, Institut de Neurociències, Universitat Autònoma de Barcelona, Bellaterra, Spain (S.T., M.J.).
Carles JusticiaInstituto de Investigaciones Biomédicas de Barcelona (IIBB) (L.D.-M., M. Gallizioli, L.M.-K., F.R.-J., J.P., C.J., A.M.P.), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, Spain.ORCID 0000-0003-0969-6158
Miguel GueimondeInstituto de Productos Lácteos de Asturias (IPLA-CSIC), CSIC, Villaviciosa, Spain (S.A., M. Gueimonde, C.G.d.l.R.-G.).ORCID 0000-0002-0192-901X
Marcel JiménezDepartament de Biologia Cel.lular, Fisiologia i Inmunologia, Institut de Neurociències, Universitat Autònoma de Barcelona, Bellaterra, Spain (S.T., M.J.).ORCID 0000-0002-6602-7332
Josep Lluís TorresInstitut de Química Avançada de Catalunya (IQAC) (S.R.-R., J.L.T.), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, Spain.ORCID 0000-0002-5072-8265
Xabier UrraInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain (L.D.-M., M. Gallizioli, L.M.-K., F.R.-J., J.P., C.C., C.J., X.U., A.C., F.M.-M., A.M.P.).ORCID 0000-0002-4763-5252
Ángel ChamorroInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain (L.D.-M., M. Gallizioli, L.M.-K., F.R.-J., J.P., C.C., C.J., X.U., A.C., F.M.-M., A.M.P.).ORCID 0000-0003-0493-5340
David SanchoCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (A.M., D.S.).
Clara G de Los Reyes-GavilánInstituto de Productos Lácteos de Asturias (IPLA-CSIC), CSIC, Villaviciosa, Spain (S.A., M. Gueimonde, C.G.d.l.R.-G.).ORCID 0000-0001-9396-6311
Francesc Miró-MurInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain (L.D.-M., M. Gallizioli, L.M.-K., F.R.-J., J.P., C.C., C.J., X.U., A.C., F.M.-M., A.M.P.).ORCID 0000-0003-3936-2693
Anna M PlanasInstituto de Investigaciones Biomédicas de Barcelona (IIBB) (L.D.-M., M. Gallizioli, L.M.-K., F.R.-J., J.P., C.J., A.M.P.), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, Spain.ORCID 0000-0002-6147-1880
Institut d'Investigacions Biomèdiques de Barcelona · ESHospital Clínic de Barcelona · ESInstituto de Productos Lácteos de Asturias · ESInstitute of Advanced Chemistry of Catalonia · ESSpanish National Centre for Cardiovascular Research · ESUniversitat Autònoma de Barcelona · ESDepartament de Salut · ESVall d'Hebron Institut de Recerca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRespiratory and urinary tract infections are frequent complications in patients with severe stroke. Stroke-associated infection is mainly due to opportunistic commensal bacteria of the microbiota that may translocate from the gut. We investigated the mechanisms underlying gut dysbiosis and poststroke infection.

methodsUsing a model of transient cerebral ischemia in mice, we explored the relationship between immunometabolic dysregulation, gut barrier dysfunction, gut microbial alterations, and bacterial colonization of organs, and we explored the effect of several drug treatments.

resultsStroke-induced lymphocytopenia and widespread colonization of lung and other organs by opportunistic commensal bacteria. This effect correlated with reduced gut epithelial barrier resistance, and a proinflammatory sway in the gut illustrated by complement and nuclear factor-κB activation, reduced number of gut regulatory T cells, and a shift of gut lymphocytes to γδT cells and T helper 1/T helper 17 phenotypes. Stroke increased conjugated bile acids in the liver but decreased bile acids and short-chain fatty acids in the gut. Gut fermenting anaerobic bacteria decreased while opportunistic facultative anaerobes, notably Enterobacteriaceae, suffered an expansion. Anti-inflammatory treatment with a nuclear factor-κB inhibitor fully abrogated the Enterobacteriaceae overgrowth in the gut microbiota induced by stroke, whereas inhibitors of the neural or humoral arms of the stress response were ineffective at the doses used in this study. Conversely, the anti-inflammatory treatment did not prevent poststroke lung colonization by Enterobacteriaceae.

conclusionsStroke perturbs homeostatic neuro-immuno-metabolic networks facilitating a bloom of opportunistic commensals in the gut microbiota. However, this bacterial expansion in the gut does not mediate poststroke infection.

Indexed as

Gastrointestinal MicrobiomePneumoniaStrokeAnimalsBacteriaLungMiceNF-kappa BNF-kappa Bbacteriabile acidsbraininfectioninflammationischemia

Identifiers

PMID37226775
PMCPMC10289215
OpenAlexW4378172718

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.